InsidersTradesSigma
AVITA Medical, Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the AVITA Medical, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, AVITA Medical, Inc. has logged 108 reports. Market capitalisation: €135.4m. The latest transaction was filed on 12 June 2026 (Attribution). Among the most active insiders: O'Toole David D. All data is accessible without an account.
108
Insider Decl.
0
Thresholds
€555,444
33 ops.
Buy Volume
€2m
7 ops.
Sell Volume
46Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 21,826 of 25,927 companies
27.3
score / 100
Value8
Quality47
FCF yld-24%
Earn yld-36%
EV/EBITDA·
ROE·
Gross mgn82%
Net mgn-68%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 12 June 2026
Declarations108 total
2,000 sharesCommon StockSEC:0001193125-26-269544:0
5,200 sharesCommon StockSEC:0001193125-26-266397:0
Ideal exit: 6 Mar 2027 (T+270)
5,000 sharesCommon StockSEC:0001193125-26-263968:1
Ideal exit: 6 Mar 2027 (T+270)
5,000 sharesCommon StockSEC:0001193125-26-263968:0
Ideal exit: 6 Mar 2027 (T+270)
5,000 shares@ US$4.09990.018% mcap16.3% of flowCommon StockSEC:0001709989-26-000011:0
Ideal exit: 28 Feb 2027 (T+270)
5,000 shares@ US$4.08990.018% mcap16.2% of flowCommon StockSEC:0001709989-26-000011:1
Ideal exit: 28 Feb 2027 (T+270)
22,214 sharesCommon StockSEC:0001124181-26-000002:0
22,214 sharesCommon StockSEC:0001216486-26-000002:0
22,214 sharesCommon StockSEC:0001387652-26-000001:0
26,250 sharesCommon StockSEC:0001603289-26-000002:0
22,214 sharesCommon StockSEC:0001603289-26-000002:1
40,547 sharesCommon StockSEC:0001709989-26-000008:0
22,214 sharesCommon StockSEC:0001709989-26-000008:1
22,214 sharesCommon StockSEC:0001816242-26-000002:0
5,000 shares@ US$4.340.018% mcap25.5% of flowCommon StockSEC:0001709989-26-000006:0
Ideal exit: 26 Feb 2027 (T+270)
5,000 shares@ US$4.260.017% mcap25.1% of flowCommon StockSEC:0001709989-26-000006:1
Ideal exit: 26 Feb 2027 (T+270)
5,000 shares@ US$4.18020.017% mcap24.6% of flowCommon StockSEC:0001709989-26-000006:2
Ideal exit: 27 Feb 2027 (T+270)
5,000 shares@ US$4.20710.017% mcap24.8% of flowCommon StockSEC:0001709989-26-000006:3
Ideal exit: 27 Feb 2027 (T+270)
5,000 shares@ US$3.05150.012% mcap100.0% of flowCommon StockSEC:0001193125-26-251586:0
5,000 shares@ US$3.05150.012% mcap5.1% of flowCommon StockSEC:0001193125-26-251588:0
2,000 shares@ US$4.240.0069% mcap2.9% of flowCommon StockSEC:0001193125-26-230874:0
Ideal exit: 13 Feb 2027 (T+270)
2,000 shares@ US$4.523.0% of flowCommon StockSEC:0000950170-25-111467:0
Ideal exit: 23 May 2026 (T+270)
2,000 shares@ US$4.813.2% of flowCommon StockSEC:0000950170-25-107387:0
Ideal exit: 9 May 2026 (T+270)
11,000 shares@ US$8.3032.2% of flowCommon StockSEC:0000950170-25-036355:0
Ideal exit: 1 Dec 2025 (T+270)
10,000 shares@ US$10.0936.9% of flowCommon StockSEC:0000950170-25-024211:0
Ideal exit: 17 Nov 2025 (T+270)
25 of 108 declarations
About AVITA Medical, Inc.
AVITA Medical, Inc. is a U.S.-listed medical technology company traded on the NASDAQ under the symbol AVHHL. For French-speaking investors in Europe, it is best understood as a specialized regenerative medicine business focused on acute wound care, especially burns and traumatic skin injuries. The company’s core platform is RECELL, a cell-based autologous skin treatment system designed to help clinicians treat skin defects using a small sample of the patient’s own skin to create a cell suspension that supports healing. AVITA Medical has also expanded its portfolio with Cohealyx and PermeaDerm, broadening its footprint in advanced wound management. The company was originally founded in Australia and has since evolved into an international commercial and regulatory platform with operational headquarters in Valencia, California, United States. That U.S. base is strategically important because it places AVITA close to its primary commercial market: leading burn centers, trauma hospitals, and specialized surgical accounts across North America. Its growth story has been built around clinical innovation, regulatory approvals, and incremental expansion of real-world adoption rather than broad consumer-facing commercialization. From a competitive standpoint, AVITA Medical occupies a niche but potentially high-value segment of wound care. It competes against conventional split-thickness skin grafting and other advanced wound-care solutions. Its value proposition is centered on conserving donor skin, potentially accelerating wound closure, and improving the treatment pathway for complex burns and traumatic wounds. That differentiation is important in specialized hospital settings where clinical outcomes, operating-room efficiency, and resource utilization matter materially. Recent company updates have emphasized commercial execution, portfolio expansion, and international progress. A key development was the CE Mark approval for RECELL GO in Europe, which supports a broader international rollout and reinforces AVITA’s ambition to become a more global acute wound-care platform. Management has also highlighted operational discipline, including cost reductions and improving cash efficiency, while guiding toward a recovery in revenue momentum into 2026. For full-year 2025, AVITA Medical reported revenue of about $71.6 million and signaled an expectation of gradual normalization in clinician use of RECELL. Overall, AVITA Medical remains a differentiated but still execution-dependent medtech name on the NASDAQ in the United States. Its investment case hinges on deeper penetration within burn and trauma centers, continued regulatory and clinical validation, and the company’s ability to translate product innovation into sustainable commercial growth.
